Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07579156 · ClinicalTrials.gov registry record · NA
TearCare in Young Adults
A NA study, sponsored by University of Alabama at Birmingham.
- Not yet
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT07579156: Clinical Trial NA study, sponsored by University of Alabama at Birmingham.
NCT07579156 is a NA study that has not yet begun recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07579156, a NA study, has not yet begun recruiting, sponsored by University of Alabama at Birmingham.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study is a non-randomized, open-label, interventional trial of TearCare® eyelid warming and manual meibomian gland expression in young adults with clinically significant meibomian gland dysfunction (MGD). Intervention is with TearCare® performed at Visit 1. A single follow-up examination occurs at Day 28.
Primary Outcome
The OSDI is a 12-item questionnaire that queries a patient's symptom frequency, situational context, and environmental triggers.
Interventions
- DEVICE TearCare®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2027-12-01 |
| Phase | NA |
What is known before NCT07579156 opens enrollment
NCT07579156 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which TearCare® is the first listed.
NCT07579156 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07579156 about?
NCT07579156 is a clinical study titled "TearCare in Young Adults". This study is a non-randomized, open-label, interventional trial of TearCare® eyelid warming and manual meibomian gland expression in young adults with clinically significant meibomian gland dysfunction (MGD). Intervention is with TearCare® performed at Visit 1. A single follow-up examination occurs...
What is the current status of trial NCT07579156?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2026-08-01. Estimated completion is 2027-12-01.
What interventions are being tested in trial NCT07579156?
The interventions under investigation include: TearCare® (DEVICE).
Who is sponsoring clinical trial NCT07579156?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07579156's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI